Treatment with Combination of Mithramycin A and Tolfenamic Acid Promotes Degradation of Sp1 Protein and Synergistic Antitumor Activity in Pancreatic Cancer

Previous studies showed that both mithramycin (MIT) and tolfenamic acid (TA) inhibits the activity of the transcription factor Sp1. In the present study, we sought to determine whether treatment with a combination of these two compounds has a synergistic effect on Sp1 activity and pancreatic cancer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jia, Zhiliang, Gao, Yong, Wang, Liwei, Li, Qiang, Zhang, Jun, Le, Xiangdong, Wei, Daoyan, Yao, James C., Chang, David Z., Huang, Suyun, Xie, Keping
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2840649/
https://ncbi.nlm.nih.gov/pubmed/20086170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-3282
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados